GHK-Cu (Copper Tripeptide-1)

A Clinical Learning Guide for Medical Providers

Endogenous Copper-Binding Tripeptide • Glycyl-L-Histidyl-L-Lysine • Skin Resilience (matrix-rebuilding / foundational peptide)

Evidence base at a glance: GHK-Cu is the FOUNDATIONAL Skin Resilience peptide — the matrix rebuilder — and the only one in this group that crosses categories: the same molecule appears in Recovery & Gut Stabilization, because its actions run "inside-out." Three facts dominate: (1) it is an ENDOGENOUS copper-binding tripeptide (Gly-His-Lys:Cu2+, MW ~401 Da) discovered by Pickart in 1973, whose plasma level falls by more than half between ages 20 and 60 — so the core premise is restoring a youthful signal that declines with age, not adding a foreign drug; (2) its signature action is REBUILDING the dermal matrix — topical GHK-Cu raises collagen ~70% in human skin biopsies (more than vitamin C or retinoic acid) and reduced wrinkle volume ~55% in a randomized double-blind trial — while acting as a broad gene modulator (>4,000 genes in vitro) that engages TGF-β/SMAD, NF-κB, and Nrf2/ARE; (3) the evidence is sharply SPLIT — topical/cosmetic use is human-validated and decades-safe, but every systemic claim (cancer, COPD, IBD, neuroprotection) is preclinical or anecdotal, with NO human pharmacokinetics on any route and injectable forms flagged by the FDA for immunogenicity. A validated topical matrix-builder; an unvalidated systemic extrapolation.

1. Peptide Profile

Name: GHK-Cu / Copper Tripeptide-1 / Glycyl-L-Histidyl-L-Lysine:Copper(II)

Classification: Endogenous copper-binding tripeptide; a matricellular signaling molecule active in tissue repair, remodeling, and gene regulation (not a structural protein)

Discovery: Identified by Loren Pickart in 1973 from human plasma albumin; also liberated in tissue from SPARC (osteonectin) via plasmin proteolysis

Structure: Gly-His-Lys:Cu2+ — a 3-amino-acid peptide chelating a copper(II) ion; MW 400.90 Da; copper affinity log10 K = 16.44 (higher than albumin's, which is why it captures and "silences" free copper)

Plasma level / age: ~200 ng/mL at age 20, declining to ~80 ng/mL by age 60 — the age-related fall underpins the "restore what is lost" rationale

Primary action: Rebuilds and remodels the dermal extracellular matrix (↑ collagen I/III, elastin, glycosaminoglycans) and acts as a broad transcriptional modulator (>4,000 genes in vitro) coordinating regenerative, antioxidant, and anti-inflammatory programs

FDA / regulatory status: NOT approved for any human indication. Legal as a topical cosmetic ingredient (Copper Tripeptide-1) only while no disease/mechanism claims are made; systemic/injectable use is compounding-only, and injectable forms were flagged for immunogenicity risk

Formulations / routes: Topical 0.01–1% cream/gel/serum (validated cosmetic); subcutaneous 0.5–2.5 mg/day compounded (anecdotal); intranasal ~35 µg/spray (investigational, neuro); no published IV/human PK data

Where It Sits in the Skin Resilience Group

GHK-Cu is the first and foundational peptide of the Skin Resilience series, and it takes the matrix-rebuilding approach. Where Leuphasyl and Argireline relax the expression muscles, and the Melanotans build UV defense through pigment, GHK-Cu rebuilds the dermal scaffold itself — collagen, elastin, and glycosaminoglycans — and resets the gene programs behind repair. It is also the one peptide in this group that crosses categories: the same molecule is taught under Recovery & Gut Stabilization, because Dr. Seeds frames its action as "inside-out" — used topically on skin, and systemically (subcutaneously) on the very same repair, antioxidant, and anti-inflammatory pathways. This guide emphasizes the skin-resilience use; the systemic discussion lives mainly in the recovery series.

The Endogenous-Replacement Rationale & Copper-Chaperone Role

Because GHK-Cu is something the body already makes — and makes progressively less of with age — its premise differs from synthetic actives: it is less about adding a drug than about restoring a youthful signal. It also functions as a copper chaperone, escorting copper(II) to where it is needed while preventing the loose, redox-active free copper that would otherwise drive Fenton-type oxidation. Its very high copper affinity (log K 16.44) is exactly what lets it "silence" free-copper redox: copper is held tightly within the tripeptide and exchanged rapidly and specifically with partner molecules, rather than left free to do damage. This copper-delivery role is the theory Dr. Seeds offers as the possible upstream "master switch" behind GHK-Cu's many downstream effects.

Topical vs Systemic: The Inside-Out Question

The defining honest split for GHK-Cu is route. Topically, for skin resilience, the human evidence is solid and the safety record spans decades. Systemically — the "inside-out" approach of subcutaneous dosing to work on the same fibroblast, keratinocyte, antioxidant, and anti-inflammatory pathways from within — the rationale is mechanistically rich but clinically unproven: there is no human pharmacokinetic data on any route, all systemic dosing is extrapolated from animals and anecdote, and injectable forms were removed from compounding lists over immunogenicity concerns (a status that may yet change). Keeping the validated topical use distinct from the unvalidated systemic extrapolation is the single most important framing for this peptide.

2. Modes of Action & Mechanisms

GHK-Cu does not act through a single identified receptor — no specific cell-surface receptor has been found, which is itself a key gap. Instead it delivers copper and reprograms gene expression broadly: one input fans out into matrix rebuilding, a context-dependent TGF-β/SMAD switch, NF-κB suppression, Nrf2 antioxidant activation, and several additional pathways, with modulation of more than 4,000 genes reported in vitro. For the skin, the matrix-remodeling arm is the clinically validated one; the rest is compelling rationale drawn largely from animal and cell models.

Mechanism 1: Extracellular Matrix Remodeling (the skin-resilience core)

- **Collagen:** ↑ collagen I/III synthesis — ~70% in human skin biopsies, exceeding vitamin C (~50%) and retinoic acid (~40%)

- **Elastin & ground substance:** ↑ elastin (+40–60%), fibronectin, decorin, dermatan sulfate, and other glycosaminoglycans
- **MMP/TIMP balance:** ↑ TIMP-1 at all concentrations, with low-nM ↑ of MMP-1/2 — net effect is balanced matrix preservation, not breakdown
- **Dose-dependent in vivo:** collagen synthesis roughly twice that of non-collagen proteins in rat wound chambers — balanced remodeling rather than fibrotic scarring

Mechanism 2: TGF-β / SMAD Modulation (the bidirectional switch)

The conceptual key to GHK-Cu is that it is a MODULATOR, not a one-way stimulator. In fibrosis it SUPPRESSES TGF-β1 mRNA/protein, phospho-Smad2/3, and IGF-1 dose-dependently, and inhibits epithelial-to-mesenchymal transition (↓ vimentin, ↓ α-SMA, ↑ E-cadherin) — i.e., it acts anti-fibrotic. But in active wound repair it ACTIVATES TGF-β-consistent gene patterns and raises integrin β1 — i.e., it acts pro-regenerative. This disease-context switching between anti-fibrotic and pro-regenerative modes is what lets it rebuild without scarring.

Mechanism 3: NF-κB Inhibition & Nrf2/ARE Activation

- **NF-κB inhibition:** blocks p65 nuclear translocation; ↓ TNF-α, IL-6, IL-1β by roughly 40–70% (1–5 μM)
- **Nrf2/ARE activation:** drives antioxidant transcription at the antioxidant-response element → ↑ superoxide dismutase and glutathione peroxidase expression
- **Iron / Fenton control:** blocks ferritin iron release by ~87%, preventing Fenton oxidation in damaged tissue
- **LDL oxidation:** 100% block of anti-LDL oxidation in one model, versus ~20% protection from SOD1 — a striking but preclinical antioxidant signal

Additional Pathways & the Copper-Chaperone Theory

- **SIRT1/STAT3:** ↑ SIRT1, ↓ phospho-STAT3, ↑ ZO-1/occludin → mucosal healing in a colitis model (2025)
- **Wnt/β-catenin:** activated in a hair-follicle model → ↑ VEGF
- **p53 family / apoptosis:** ↑ p63 and p73 (reported +938%), caspase and ATM/BRCA1 changes — epithelial stem-cell activation and cell survival (in vitro)
- **MAPK & insulin/IGF-1:** blocks p38 MAPK in acute lung injury; reverses bleomycin-induced IGF-1 rise in pulmonary fibrosis
- **Copper chaperone (theoretical):** cellular copper delivery may be the upstream master switch unifying all of the above

Pathways at a Glance

Pathway	Effect	Evidence
ECM remodeling	↑ collagen I/III, elastin, GAGs; balanced MMP/TIMP	Human + preclinical
TGF-β / SMAD	Bidirectional: anti-fibrotic in fibrosis, pro-regenerative in repair	Preclinical
NF-κB	↓ TNF-α, IL-6, IL-1β by 40–70%	Preclinical

Pathway	Effect	Evidence
Nrf2 / ARE	↑ SOD, GPx; ~87% iron-release block; antioxidant	In vitro
SIRT1 / STAT3	Mucosal healing (colitis model)	Preclinical
Wnt, p53, MAPK, IGF-1	Hair/VEGF, stem-cell & apoptosis control, anti-inflammatory	Preclinical / in vitro

Mechanistic takeaway: GHK-Cu has no known single receptor — it works as a copper chaperone and a broad gene modulator. For SKIN, that translates into a clean, well-supported story: more collagen, elastin, and GAGs, balanced MMP/TIMP remodeling, and fewer wrinkles. The deeper systemic mechanisms — the bidirectional TGF-β switch, simultaneous NF-κB suppression and Nrf2 activation, and >4,000-gene modulation — are mechanistically striking but largely in vitro or animal: compelling rationale, not yet human proof.

3. Points of Clinical Relevance

1. The skin evidence is genuinely strong

Among topical actives, GHK-Cu is unusually well supported: ~70% collagen increase in human skin biopsies (greater than vitamin C or retinoic acid), ~55% reduction in wrinkle volume in a randomized double-blind trial, measurable gains in firmness/density/thickness within 8–12 weeks, accelerated healing of experimental skin wounds, and decades of cosmetic safety with no serious adverse effects reported. For cosmetic skin use, this is a credible, evidence-backed choice.

2. It is a replacement, not just an additive

GHK-Cu is endogenous and declines with age (plasma ~200 → 80 ng/mL from 20 to 60). The therapeutic logic is restorative — returning a youthful repair signal — which is conceptually different from layering on a synthetic active, and helps explain its broad, “normalizing” pattern of effects.

3. The TGF-β switch is the conceptual key

Its bidirectional behavior — anti-fibrotic where there is excess fibrosis, pro-regenerative where repair is needed — is why it behaves as a modulator that promotes balanced remodeling rather than scar. This is the single most important mechanistic idea to carry forward, even though most of the supporting data is preclinical.

4. Topical is validated; systemic is not

This is the central honesty of the peptide. Topical skin use is human-validated; subcutaneous/systemic dosing is anecdotal, with no human pharmacokinetics on any route, and injectable forms were flagged by the FDA for immunogenicity. Keep these two uses cleanly separated when counseling patients.

5. Copper handling is the safety crux

GHK-Cu silences free-copper redox through its very high copper affinity, so at therapeutic doses copper toxicity is low-risk (toxic threshold reported at ~300× therapeutic). The real-world hazard is product quality: cheap or counterfeit “copper peptide” products that simply add free copper for color — not a properly conjugated tripeptide — are where matrix-metalloproteinase-driven collagen fragmentation (“copper uglies”) and copper toxicity actually arise.

6. Contraindications follow from copper biology

Wilson's disease is an absolute contraindication (a copper-overload disorder); active or suspected malignancy is avoided on theoretical angiogenic grounds; and pregnancy/lactation warrant caution. Copper chelators (D-penicillamine, trientine) and high-dose zinc may compete for copper and reduce efficacy. No formal drug-interaction studies exist.

7. The vitamin-C timing question

A common worry is that applying topical vitamin C (ascorbic acid) close to GHK-Cu could reduce its copper and blunt it. Dr. Seeds regards this as theoretical and largely unfounded — copper exchange within the tripeptide is rapid and specific, silencing free copper — but suggests, as a simple practical hedge, spacing the two products by about 20 minutes to sidestep the question entirely.

4. General Dosing & Delivery Options

Only TOPICAL dosing is human-validated. Systemic (subcutaneous, intranasal) protocols are compounding-grade and anecdotal, extrapolated from animal data, with NO human pharmacokinetics on any route. The figures below are educational context, not a validated regimen.

Dosing & Administration

Route / Protocol	Dose	Evidence
Topical (validated)	0.01–1% cream/gel, twice daily, 8–12 weeks	Human cohort
In-vitro active range	0.01–10 nM (fibroblasts); ~1 µM (gene expression)	In vitro
Subcutaneous (compounded)	0.5–2.5 mg/day, 30 days on / 30 off; or ~1–2 mg twice daily, 6–12 wk then 6 wk off	Anecdotal
Intranasal (investigational)	~35 µg/spray (neuroprotective rationale)	Emerging
Systemic animal data	1.1 mg/kg IV (pigs); 0.5 µg/kg IP (rats)	Preclinical
Enhanced delivery	Liposomes, nanocarriers, ionic-liquid microemulsions (~3× improvement)	Preclinical

Pharmacokinetics (what little is known)

- **Plasma half-life:** ~30–60 minutes — rodent data only; no human PK

- **Cellular effects:** persist ~48–96 hours after clearance (continued collagen synthesis and gene expression)
- **Topical penetration:** crosses the stratum corneum; enhanced by nanocarriers/liposomes
- **Copper exchange:** rapid between GHK molecules and partners, which silences copper redox
- **Major gap:** no published Cmax, AUC, bioavailability, distribution, or metabolism data in humans on any route

Synergies & Combinations

- **With vitamin C / retinoids:** commonly layered for collagen support; space ~20 minutes from GHK-Cu as a practical hedge (interference is theoretical)
- **Delivery vehicles:** liposomes, nanocarriers, and ionic-liquid microemulsions improve penetration (preclinical ~3×)
- **Relationship to Matrixyl 3000:** Matrixyl is palmitoyl-GHK (Pal-GHK), a synthetic lipophilic cousin built for skin penetration; GHK-Cu is the endogenous copper form — both cosmetic, neither systemically approved

5. Evidence Profile

Evidence tier distribution: the bottom line is 1 human RCT, 9 preclinical studies, and 5 in-vitro studies. Topical skin/cosmetic (and plausibly wound-care) use is human-validated and decades-safe; everything systemic is preclinical or anecdotal. The >4,000-gene story and bidirectional TGF-β modulation are extraordinary but unvalidated in human tissue in vivo. The single strongest human datum is Badenhorst 2016 (wrinkle volume −55.8%, p<0.001).

Key Studies

Author / Year	Design	Key Outcome
Badenhorst 2016	Randomized double-blind, 3-arm	Wrinkle volume −55.8% (p<0.001) [RCT]
Abdulghani 1998	Controlled (topical)	Collagen +70% on biopsy, > vit C / retinoic acid [Cohort]
Maquart 1993	Controlled, rat wound chambers	Dose-dependent ↑ collagen and GAG [Preclinical]
Zhou 2017	Bleomycin mice, 3 doses	↓ TGF-β1/Smad, ↓ IGF-1 (anti-fibrotic) [Preclinical]
Ma 2020	Bleomycin mice	Nrf2 + NF-κB + TGF-β (antioxidant/anti-inflammatory) [Preclinical]
Mao 2025	DSS mice (colitis)	SIRT1/STAT3, mucosal healing [Preclinical]

Cross-Category Mechanistic Studies (Recovery / Systemic)

- **Pulmonary fibrosis (Zhou 2017; Ma 2020):** anti-fibrotic via TGF-β/Smad suppression plus Nrf2/NF-κB modulation in bleomycin models
- **Emphysema (Campbell 2012):** GHK reversed an emphysema-related lung-destruction gene signature
- **Colitis / IBD (Mao 2025):** SIRT1/STAT3-mediated mucosal healing — the link to the Recovery & Gut series
- **Cancer cell lines (MCF7/PC3):** Connectivity-Map gene modulation — interesting but does not predict in-vivo response
- **Neuro (Pickart 2017):** gene-expression changes relevant to cognition; intranasal copper signal under investigation

Critical gaps: I cannot confirm efficacy for ANY systemic human disease (cancer, COPD, IBD, neurodegeneration); there is NO human pharmacokinetic data for any route; injectable safety is unconfirmed (FDA immunogenicity concern); MCF7 Connectivity-Map data does not predict normal in-vivo tissue response; there is no large-scale RCT (N>200) for any indication; systemic dosing is entirely anecdotal; long-term safety of chronic systemic copper (accumulation, immune effects) is unknown; and no specific cell-surface receptor has been identified. The first registered RCT (NCT07437586, topical wound-healing gel, China) was posted in February 2026 with no results yet.

6. Clinical Considerations

Contraindications & Cautions

- **Wilson's disease:** absolute contraindication — a copper-overload disorder
- **Active or suspected malignancy:** avoid on theoretical angiogenic grounds
- **Pregnancy / lactation:** use caution (insufficient data)
- **Hypersensitivity / counterfeit product:** avoid non-conjugated “copper peptide” products that add free copper

Drug Interactions

No published drug-interaction studies exist. On mechanistic grounds, copper chelators (D-penicillamine, trientine) may compete for copper and reduce efficacy, and high-dose zinc may lower copper availability (and potentially endogenous GHK-Cu). These interactions are theoretical; document concurrent copper-active agents and chelators.

Monitoring Parameters

Parameter	Frequency	Rationale
Skin response + irritation	Through an 8–12-week topical course	Track firmness/wrinkle change; detect redness/itch/allergy
Product authenticity / quality	Each product	Avoid free-copper counterfeits (“copper uglies” risk)

Parameter	Frequency	Rationale
Route / dose / cycle (if systemic)	Each use	All systemic use is unvalidated — document for safety and audit
Copper-status awareness	If chronic systemic use	No validated biomarker; watch in chelator/high-zinc/Wilson's contexts

Cadence: for skin resilience, use a properly conjugated 0.01–1% GHK-Cu cream/gel twice daily and reassess at 8–12 weeks; layer vitamin C or retinoids with ~20-minute spacing if desired. There is no validated biomarker to monitor response, so track clinical/photographic skin change. Any systemic (subcutaneous or intranasal) use is unvalidated — verify genuine product, obtain informed consent, and document route, dose, and on/off cycling so the experience can be reviewed.

Safety Profile

- **Topical:** decades of cosmetic use; mild, transient redness, itching, or irritation; rare allergic reactions
- **"Copper uglies" (anecdotal):** excess/free copper → possible ↑ MMP and collagen fragmentation — seen mainly with non-conjugated counterfeit products
- **Copper toxicity:** low risk at therapeutic doses; GHK silences copper redox; toxic threshold ~300× therapeutic
- **Injectable:** no published human safety data; FDA notes immunogenicity risk from compounded formulations (status may change)

Regulatory Status

GHK-Cu is NOT FDA-approved for any indication. It is legal as a topical cosmetic ingredient (Copper Tripeptide-1) provided no disease or mechanism claims are made — which is precisely why no human PK or efficacy data is required for its cosmetic sale. Systemic and injectable use is compounding-only and was flagged for immunogenicity; all therapeutic claims remain investigational.

7. Final Note

GHK-Cu is the foundational peptide of the Skin Resilience series and its matrix rebuilder: rather than relaxing expression muscles (Leuphasyl, Argireline) or driving protective pigment (the Melanotans), it restores the dermal scaffold — collagen, elastin, and glycosaminoglycans — and resets the gene programs of repair. It is also the bridge to the Recovery & Gut Stabilization series, because the same molecule is used "inside-out": topically on skin and systemically on the same pathways. Its defining features are that it is endogenous (declining with age, so its logic is restorative), and that it works as a copper chaperone and broad gene modulator with no single known receptor.

The honest framing is a clean split by route. For topical skin use, the evidence is real and reassuring: ~70% more collagen than competing actives, ~55% less wrinkle volume in a randomized trial, balanced (non-scarring) remodeling, and decades of safety. For systemic use, the picture inverts: the mechanisms (a bidirectional TGF-β switch, simultaneous NF-κB

suppression and Nrf2 activation, >4,000-gene modulation) are genuinely compelling, but they are largely in vitro and animal, with no human pharmacokinetics, no large RCT, anecdotal dosing, and an injectable form flagged for immunogenicity.

For the clinician, GHK-Cu is best understood as two things held apart: a validated, low-risk topical matrix-builder for skin resilience and wound support, and an investigational systemic peptide whose extraordinary gene-modulation story is not yet confirmed in humans. Used topically, with genuine conjugated product and realistic expectations, it is one of the better-supported tools in the aesthetic toolbox. Used systemically, it should be treated as experimental — carefully documented, consented, and watched — until the human data (beginning with the first registered RCT) arrives.

Bottom line: An ENDOGENOUS copper-binding tripeptide (Gly-His-Lys:Cu2+, ~401 Da) that declines with age and acts as a copper chaperone and broad gene modulator (>4,000 genes in vitro) with no single known receptor. Its signature is REBUILDING the dermal matrix — ~70% more collagen than vitamin C/retinoic acid, ~55% less wrinkle volume in a randomized trial, balanced remodeling via the bidirectional TGF-β switch, plus NF-κB suppression and Nrf2 antioxidant activation. TOPICAL use is human-validated and decades-safe; SYSTEMIC use is preclinical/anecdotal with no human PK and FDA-flagged injectable immunogenicity. NOT FDA-approved; cosmetic-legal as Copper Tripeptide-1. The foundational Skin Resilience peptide — and the bridge to Recovery & Gut Stabilization.

Selected References

1. Pickart L, Freedman JH, Loker WJ, et al. Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature. 1980;288(5792):715–717.

2. Maquart FX, Pickart L, Laurent M, et al. Stimulation of collagen synthesis in fibroblast cultures by GHK-Cu2+. FEBS Lett. 1988;238(2):343–346.

3. Maquart FX, Bellon G, Chaqour B, et al. In vivo stimulation of connective tissue accumulation by GHK-Cu2+ in rat experimental wounds. J Clin Invest. 1993;92(5):2368–2376.

4. Abdulghani AA, Sherr S, Shirin S, et al. Effects of topical creams containing vitamin C, a copper-binding peptide cream, and melatonin compared with tretinoin. Dis Manag Clin Outcomes. 1998;1(4):136–141. [Cohort]

5. Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Res Int. 2015;2015:648108. [Review]

6. Pickart L, Vasquez-Soltero JM, Margolina A. GHK-Cu may prevent oxidative stress in skin by regulating copper and modifying expression of antioxidant genes. Cosmetics. 2015;2(3):236–247. [In Vitro]

7. Badenhorst T, Svirskis D, Merrilees M, et al. Effects of GHK-Cu on MMP and TIMP expression, collagen and elastin production, and facial wrinkle parameters. J Aging Sci. 2016;4(3):166. [RCT]

8. Campbell JD, McDonough JE, Zeskind JE, et al. A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Med. 2012;4(8):67. [Preclinical]

9. Zhou XM, Wang GL, Wang XB, et al. GHK peptide inhibits bleomycin-induced pulmonary fibrosis by suppressing TGFβ1/Smad-mediated EMT. Front Pharmacol. 2017;8:904. [Preclinical]

10. Ma WH, Li M, Ma HF, et al. Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways. Life Sci. 2020;241:117139. [Preclinical]

11. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. [Review]

12. Pickart L, Vasquez-Soltero JM, Margolina A. The effect of the human peptide GHK on gene expression relevant to nervous system function and cognitive decline. Brain Sci. 2017;7(2):20. [In Vitro / Review]

13. Mao S, Huang J, Li J, et al. Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms. Front Pharmacol. 2025;16:1551843. [Preclinical]

14. Pickart L, Margolina A. Modulation of gene expression in human breast cancer MCF7 and prostate cancer PC3 cells by GHK-Cu. OBM Genet. 2021;5(2):1–18. [In Vitro]

15. Liu T, Liu Y, Zhao X, et al. Thermodynamically stable ionic liquid microemulsions pioneer pathways for topical delivery and peptide application. Bioactive Mater. 2024;32:502–513. [Preclinical]

For educational and research purposes only. Not medical advice. GHK-Cu / Copper Tripeptide-1 is NOT FDA-approved for any indication; it is legal only as a topical cosmetic ingredient when no disease or mechanism claims are made. Topical skin use is human-validated with decades of cosmetic safety; ALL systemic uses (subcutaneous, intranasal, injectable) are preclinical or anecdotal, with no human pharmacokinetic data on any route, and injectable forms were flagged by the FDA for immunogenicity risk. Wilson's disease is an absolute contraindication; active malignancy and pregnancy/lactation warrant caution. Use only genuine conjugated copper-tripeptide product. The foundational peptide of the Skin Resilience series and the bridge to Recovery & Gut Stabilization. Based on lecture materials by William Seeds, MD — SSRP Institute | Cellular Medicine Education.